No­vavax says its vac­cine is 80% ef­fec­tive in teens, but man­u­fac­tur­ing ques­tions con­tin­ue to cloud fu­ture

No­vavax fi­nal­ly sub­mit­ted an ap­pli­ca­tion for emer­gency use au­tho­riza­tion for its Covid-19 vac­cine late last month. Now a sec­ond ap­pli­ca­tion may al­ready be in the off­ing.

The oft-de­layed but nev­er-bor­ing Mary­land-based vac­cine com­pa­ny an­nounced pos­i­tive re­sults from its ado­les­cent tri­al on Thurs­day. The biotech’s vac­cine, known as Nu­vax­ovid, was 80% ef­fec­tive at pre­vent­ing symp­to­matic dis­ease in pa­tients 12 to 17 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER